Skip to content
‹ Back to IndustriesSciences

As Spaces Evolves into a “Normal Market”, How Will This Impact the Competition?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration. In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · Space CommerceSpace Commerce ConsultingSpace EconomySpace Finance Community
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant for companies throughout the globe. As founder and CEO of Space Economy Rising, LLC, O’Connell speaks to the past and future of space commerce. With decades of experience working within government institutions, including the White House as well as speaking before US Congress committees on a variety of issues, O’Connell is uniquely positioned to provide insight into an industry that is both elusive and relevant.

When asked about his transition to the private sector, O’Connell spoke to his decision as follows:

“We’ve had a lot of folks talk to us over the last few years to say hey Kevin you just have to slow this all down. You have to slow all of this work down, especially in lower earth orbit. And, our view was that we looked very hard for data driven approaches to regulation we were going to regulate. What would be the analytic basis upon which we would do it.

We worked with the FCC when they issued their orbital debris mitigation guidelines to say okay what pieces of this rule are supported by what kinds of evidence. And, in a lot of cases there was a lot of wishful thinking but there wasn’t a lot of data rigorously collected to support that. And I would say that regulation that is uninformed and just based on wishful thinking can really do tremendous damage to an industry. So, you have to think about it that way. I think you do.”

This intriguing podcast goes on to explore O’Connell’s transition out of government and to what he is doing now in the private sector as well as what lessons he is bringing forward into his present business.

Of the many hats O’Connell wears, the most significant of his present contributions is in the field of space economy. This includes advising companies on

  • Space Industry
  • Technology
  • Space finance community
  • Basics that must be done as an early-stage company in this field
  • Competitors
  • Orbital debris mitigation strategies
  • Cyber security strategies
  • Investment Risk Management
  • And much more.

Tune in to learn from this renowned expert as the discussion covers everything from how he got to where he is to what he envisions for the future of space economy.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512